Abstract: Immune cells expressing IL-7, CCL19, or a combination thereof, and a composition containing the immune cells, which is useful for preventing or treating cancer or infectious diseases are disclosed. A method for preventing or treating cancer or infectious diseases, which include administering a therapeutically effective amount of single type of immune cells, specifically natural killer cells, is also disclosed. Complementary immune responses between the patient's endogenous T cells and injected natural killer cells exhibit multifaceted and synergistic therapeutic effects. Co-administration of T cells and the immune cells other than T cells, specifically natural killer cells, also significantly improves therapeutic effects by allowing these heterogeneous cell populations to act in a lesion-concentrated manner.

Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.

Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.

Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.

Abstract: The present invention relates to methods of delivering nucleic acids into cells using a nucleic acid binding molecule containing a multimeric or spacer-incorporated protein transduction domain (PTD). The invention also relates to novel compositions that contain a nucleic acid complexed or conjugated with a nucleic acid binding molecule. The nucleic acid binding molecule may contain a multimeric or spacer-incorporated PTD, and may further contain a nucleic acid binding region. The nucleic acid complexes or conjugations of the present invention may be employed to inhibit expression of a target gene, and/or determine the function of a target gene.

Abstract: The present invention relates to methods of delivering nucleic acids into cells using a nucleic acid binding molecule containing a multimeric or spacer-incorporated protein transduction domain (PTD). The invention also relates to novel compositions that contain a nucleic acid complexed or conjugated with a nucleic acid binding molecule. The nucleic acid binding molecule may contain a multimeric or spacer-incorporated PTD, and may further contain a nucleic acid binding region. The nucleic acid complexes or conjugations of the present invention may be employed to inhibit expression of a target gene, and/or determine the function of a target gene.

Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.

Abstract: Disclosed in this invention are an expression vector for the secretive production of human interferon alpha (hIFN?) comprising a polynucleotide encoding a modified E. coli thermostable enterotoxin II signal sequence and a polynucleotide encoding hIFN? ligated to the 3?-end thereof; a microorganism transformed with the expression vector; and a process for secretively producing human interferon by culturing the microorganism, the process being capable of secreting a soluble form of active hIFN?, which does not contain an additional methionine residue at its N-terminal, into the periplasm of an E. coli cell.

Abstract: Disclosed in this invention are: an expression vector for the secretive production of human interferon alpha (hIFN&agr;) comprising a polynucleotide encoding a modified E. coli thermostable enterotoxin II signal sequence and a polynucleotide encoding hIFN&agr;) ligated to the 3′-end thereof; a microorganism transformed with the expression vector, and a process for secretively producing human interferon by culturing the microorganism, said process being capable of secreting a soluble form of active hIFN&agr;), which does not contain an additional methionine residue at its N-terminal, into the periplasm of an E coli cell.

Abstract: A heterologous protein is produced by: (i) culturing a microorganism transformed with an expression vector comprising a gene encoding a modified E. coli enterotoxin II signal peptide fused with the heterologous protein to produce and secrete the heterologous protein to periplasm, the modified E. coli enterotoxin II signal peptide being obtained by replacing at least one of the 2nd, 4th, 5th, 12th, 20th, and 22nd amino acids of E. coli enterotoxin II signal peptide of the following amino acid sequence (SEQ ID NO: 1) with another amino acid, with the proviso that at least one of the 2nd and 4th amino acid of the modified peptide is lysine; and (ii) recovering the heterologous protein from the periplasm.